Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasiprotimut-T - Biovest International

Drug Profile

Dasiprotimut-T - Biovest International

Alternative Names: Autologous immunoglobulin follicular lymphoma idiotype vaccine - Biovest/NCI; B-cell lymphoma vaccine - Biovest; BiovaxID; FNHLId1; Lympreva

Latest Information Update: 29 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Biovest International; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Follicular lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 16 Jun 2021 The National Cancer Institute completes a phase II trial in Mantle cell lymphoma in USA (NCT00005780)
  • 12 Jul 2017 Discontinued - Phase-II for Mantle cell lymphoma in USA (SC)
  • 12 Jul 2017 Discontinued - Phase-III for Follicular lymphoma (Late-stage disease) in Russia and Ukraine (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top